Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL)

被引：0
|
作者：
Brummendorf, T. H.
Cortes, J. E.
Kantarjian, H.
Gambacorti-Passerini, C.
Baccarani, M.
Kim, D.
Zaritskey, A.
Navarro, J.
Rapoport, A.
Dorlhiac-Llacer, P. E.
Milone, J.
Zanichelli, M.
Besson, N.
Leip, E.
Kelly, V.
Khoury, H. J.
机构：
[1] Rhein Westfal TH Aachen, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Aachen, Germany
[2] RWTH, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Hamburg, Germany
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Milano Bicocca, Monza, Italy
[5] Univ Bologna, Bologna, Italy
[6] Seoul St Marys Hosp, Seoul, South Korea
[7] Univ Pavlov, St Petersburg, Russia
[8] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[9] Greenebaum Canc Ctr, Baltimore, MD USA
[10] FMUSP, Hosp Clin, Sao Paulo, Brazil
[11] Inst Trasplante Medula Osea, La Plata, Buenos Aires, Argentina
[12] Univ Sao Paulo, Childrens Inst, Sao Paulo, Brazil
[13] Pfizer Global Res & Dev, Paris, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Emory Univ, Sch Med, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6535
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial
    Khoury, H. Jean
    Cortes, Jurge E.
    Kantarjian, Hagop
    Baccarani, Michele
    Shah, Neil P.
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Hochhaus, Andreas
    BLOOD, 2010, 116 (21) : 1401 - 1401
  • [32] Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)
    Wang, Jianxiang
    Huang, Xiaojun
    Hu, Jianda
    Li, Jianyong
    Jin, Jie
    Meng, Fanyi
    Shen, Zhixiang
    Liu, Ting
    Wu, Depei
    Wang, Jianmin
    LEUKEMIA & LYMPHOMA, 2013, 54 : 3 - +
  • [33] Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib.
    Jabbour, Elias
    Kantarjian, Hagop
    Giles, Francis
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 616A - 616A
  • [34] Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
    Naqvi, Kiran
    Cortes, Jorge
    Skinner, Jeffrey
    Jabbour, Elias
    Pemmaraju, Naveen
    Borthakur, Gautam
    Estrov, Zeev
    Bose, Prithviraj
    Thompson, Philip
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S15 - S16
  • [35] Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Luthra, Rajyalakshmi
    O'Brien, Susan
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 740 - 741
  • [36] Dasatinib and Nilotinib As Upfront Therapy for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in Qatar: A Cost Effectiveness Analysis (CEA)
    Adel, Ahmad M.
    Abushanab, Dina
    Hamad, Anas
    Abdulla, Mohammad Abdul-Jaber
    Yassin, Mohamed A.
    BLOOD, 2019, 134
  • [37] Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase
    袁婷
    China Medical Abstracts(Internal Medicine), 2020, 37 (02) : 111 - 112
  • [38] COMPARATIVE EFFICACY OF IMATINIB, DASATINIB AND NILOTINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): A META-ANALYSIS AND INDIRECT COMPARISON
    Park, J.
    Kwon, H.
    Shin, M.
    Shin, S.
    Lee, J. Y.
    VALUE IN HEALTH, 2015, 18 (07) : A433 - A433
  • [39] Safety and efficacy of Bosutinib in Chronoc Phase Chronic Myeloid Leukemia (CP CML)
    Bruemmendorf, T. H.
    Cortes, J.
    Schafhausen, P.
    Ordemann, R.
    Hochhaus, A.
    le Coutre, P.
    Pavlov, D.
    Leip, E.
    Duvillie, L.
    Besson, N.
    Gogat, K.
    Gambacorti-Passerini, C.
    ONKOLOGIE, 2012, 35 : 48 - 48
  • [40] LONG-TERM BOSUTINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR IMATINIB FAILURE
    Bruemmendorf, T. H.
    Cortes, J. E.
    Khoury, H. J.
    Kantarjian, H. M.
    Kim, D. -W.
    Schafhausen, P.
    Zeremski, M.
    Bardy-Bouxin, N.
    Shapiro, M.
    Leip, E.
    Gambacorti-Passerini, C.
    Lipton, J. H.
    HAEMATOLOGICA, 2015, 100 : 232 - 232
12345